Cargando…
β3 adrenoceptor agonist mirabegron protects against right ventricular remodeling and drives Drp1 inhibition
BACKGROUND: The right ventricular (RV) function determines the prognosis of patients with pulmonary hypertension (PH). Metabolic disorders have been observed in the RV myocardium in PH. Activation of the β3 adrenoceptor improves cardiac function and restores cardiac metabolic efficiency in rodents w...
Autores principales: | Zhao, Lin, Luo, Hui, Li, Tangzhiming, Zhao, Xiexiong, Liu, Yanghong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808120/ https://www.ncbi.nlm.nih.gov/pubmed/36605081 http://dx.doi.org/10.21037/cdt-22-274 |
Ejemplares similares
-
The metabolic effects of mirabegron are mediated primarily by β(3)‐adrenoceptors
por: Dehvari, Nodi, et al.
Publicado: (2020) -
Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder
por: Chapple, Christopher R., et al.
Publicado: (2014) -
Mirabegron, a β3‑adrenoreceptor agonist, regulates right and left atrial arrhythmogenesis differently
por: Chan, Chao-Shun, et al.
Publicado: (2022) -
Mirabegron attenuates porcine ureteral contractility via α1-adrenoceptor antagonism
por: Lim, Iris, et al.
Publicado: (2022) -
Pharmacokinetics of Mirabegron, a β(3)-Adrenoceptor Agonist for Treatment of Overactive Bladder, in Healthy Japanese Male Subjects: Results from Single- and Multiple-Dose Studies
por: Iitsuka, Hiromi, et al.
Publicado: (2013)